3-(2-叔丁氧基-2-氧代乙氧基)苯甲酸 | 313709-63-6

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(2-叔丁氧基-2-氧代乙氧基)苯甲酸
• 英文名称: 3-Carboxyphenoxyacetic acid tert-butyl ester
• 英文别名: 3-((t-butoxycarbonyl)methoxy)benzoic acid；3-(2-tert-butoxy-2-oxoethoxy)benzoic acid；3-tert-Butoxycarbonylmethoxy-benzoic acid；3-(2-(tert-Butoxy)-2-oxoethoxy)benzoic acid；3-[2-[(2-methylpropan-2-yl)oxy]-2-oxoethoxy]benzoic acid
• CAS: 313709-63-6
• 化学式: C₁₃H₁₆O₅
• 分子量: 252.267
• InChiKey: BRTRVSNTDAQAIJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  72.8
• 氢给体数：
  1
• 氢受体数：
  5

安全信息

• 海关编码：
  2918990090

反应信息

• 作为反应物：
  描述：

  3-(2-叔丁氧基-2-氧代乙氧基)苯甲酸 在 1-羟基苯并三唑 、 Rink amide MBHA resin 、 N,N'-二异丙基碳二亚胺 、 三异丙基硅烷 、 水 、 三氟乙酸 作用下， 反应 2.0h， 生成 2-(3-Carbamoylphenoxy)acetic acid
  参考文献：
  名称：

  Aminodeoxychorismate Synthase Inhibitors from One-Bead One-Compound Combinatorial Libraries:  “Staged” Inhibitor Design

  摘要：

  4-Amino-4-deoxychorismate synthase (ADCS) catalyzes the first step in the conversion of chorismate into p-aminobenzoate, which is incorporated into folic acid. We aim to discover compounds that inhibit ADCS and serve as leads for a new class of antimicrobial compounds. This report presents (1) synthesis of a mass-tag encoded library based on a "staged" design, (2) massively parallel fluorescence-based on-bead screening, (3) rapid structural identification of hits, and (4) full kinetic analysis of ADCS. All inhibitors are competitive against chorismate and Mg2+. The most potent ADCS inhibitor identified has a K-i of 360 mu M. We show that the combinatorial diversity elements add substantial binding affinity by interacting with residues outside of but proximal to the active site. The methods presented here constitute a paradigm for inhibitor discovery through active site targeting, enabled by rapid library synthesis, facile massively parallel screening, and straightforward hit identification.

  DOI：

  10.1021/jm0609869
• 作为产物：
  描述：

  间羟基苯甲酸 在 lithium hydroxide 、 水 、 potassium carbonate 、 乙酰氯 作用下， 以 四氢呋喃 为溶剂， 反应 9.0h， 生成 3-(2-叔丁氧基-2-氧代乙氧基)苯甲酸
  参考文献：
  名称：

  Aminodeoxychorismate Synthase Inhibitors from One-Bead One-Compound Combinatorial Libraries:  “Staged” Inhibitor Design

  摘要：

  4-Amino-4-deoxychorismate synthase (ADCS) catalyzes the first step in the conversion of chorismate into p-aminobenzoate, which is incorporated into folic acid. We aim to discover compounds that inhibit ADCS and serve as leads for a new class of antimicrobial compounds. This report presents (1) synthesis of a mass-tag encoded library based on a "staged" design, (2) massively parallel fluorescence-based on-bead screening, (3) rapid structural identification of hits, and (4) full kinetic analysis of ADCS. All inhibitors are competitive against chorismate and Mg2+. The most potent ADCS inhibitor identified has a K-i of 360 mu M. We show that the combinatorial diversity elements add substantial binding affinity by interacting with residues outside of but proximal to the active site. The methods presented here constitute a paradigm for inhibitor discovery through active site targeting, enabled by rapid library synthesis, facile massively parallel screening, and straightforward hit identification.

  DOI：

  10.1021/jm0609869

文献信息

• Chemical compounds
  申请人：——

  公开号：US20020077337A1

  公开（公告）日：2002-06-20

  The present invention provides a compound of a formula (I): 1 wherein the variables are defined herein; to a process for preparing such a compound; and to the use of such a compound in the treatment of a chemokine (such as CCR3) or H1 mediated disease state.

  本发明提供了一个式(I)的化合物： 1 其中变量在此处定义；用于制备这种化合物的方法；以及在治疗化学因子（如CCR3）或H1介导的疾病状态中使用这种化合物。
• Targeting Multiple Chorismate-Utilizing Enzymes with a Single Inhibitor: Validation of a Three-Stage Design
  作者：Kristin T. Ziebart、Seth M. Dixon、Belem Avila、Mohamed H. El-Badri、Kathryn G. Guggenheim、Mark J. Kurth、Michael D. Toney

  DOI：10.1021/jm100158v

  日期：2010.5.13

  with active site and surface residues, respectively, and are linked by a SPACER stage. These seven compounds, and six derivatives thereof, also inhibit two other enzymes in this family, isochorismate synthase (IS) and anthranilate synthase (AS). The best binding compound inhibits ADCS, IS, and AS with Ki values of 720, 56, and 80 μM, respectively. Inhibitors with varying SPACER lengths show the original

  分支酸利用酶是有吸引力的抗微生物药物靶点，因为它们在人类中不存在，并且它们在细菌存活和毒力中的核心作用。其中一组的结构和机制同源性激发了发现靶向多种酶的抑制剂的目标。以前，我们在 2304 成员单珠一化合物组合文库的珠上荧光筛选中发现了 7 种 4-氨基-4-脱氧分支酸合酶 (ADCS) 抑制剂。抑制剂包括 PAYLOAD 和 COMBI 阶段，它们分别与活性位点和表面残基相互作用，并通过 SPACER 阶段连接。这七种化合物及其六种衍生物还抑制该家族中的其他两种酶，即异分支酸合酶 (IS) 和邻氨基苯甲酸合酶 (AS)。最好的结合化合物抑制 ADCS、IS 和 ASķ我值分别为720，56，和80微米。具有不同 SPACER 长度的抑制剂表明赖氨酸的原始选择是最佳的。最后，抑制数据确认 PAYLOAD 阶段将抑制剂引导至 ADCS 活性部位。
• [EN] NOVEL PIPERIDINES AS CHEMOKINE MODULATORS (CCR)<br/>[FR] PIPERIDINES UTILISEES COMME MODULATEURS DES CHIMIOKINES (CCR)
  申请人：ASTRAZENECA AB

  公开号：WO2005073192A1

  公开（公告）日：2005-08-11

  Compounds of Formula (I) are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).

  式（I）的化合物是趋化因子（例如CCR3）活性的调节剂（例如用于治疗哮喘）。
• Integrin receptor antagonists
  申请人：Merck & Co., Inc.

  公开号：US06358970B1

  公开（公告）日：2002-03-19

  The present invention relates to compounds and derivatives thereof, their synthesis, and their use as integrin receptor antagonists. More particularly, the compounds of the present invention are antagonists of the integrin receptors &agr;v&bgr;3 and/or &agr;v&bgr;5 and are useful for inhibiting bone resorption, treating and preventing osteoporosis, and inhibiting vascular restenosis, diabetic retinopathy, macular degeneration, angiogenesis, atherosclerosis, inflammation, inflammatory arthritis, viral disease, cancer, and metastatic tumor growth.

  本发明涉及化合物及其衍生物、它们的合成以及它们作为整合素受体拮抗剂的用途。更具体地说，本发明的化合物是整合素受体αvβ3和/或αvβ5的拮抗剂，可用于抑制骨吸收、治疗和预防骨质疏松症，并抑制血管再狭窄、糖尿病视网膜病变、黄斑变性、血管生成、动脉粥样硬化、炎症、炎性关节炎、病毒性疾病、癌症和转移性肿瘤生长。
• Novel piperidines as chemokine modulators (ccr)
  申请人：Alcaraz Lilian

  公开号：US20070054924A1

  公开（公告）日：2007-03-08

  Compounds of formula (I): are modulators of chemokine (for example CCR3) activity (for use in, for example, treating asthma).

  公式（I）的化合物是趋化因子（例如CCR3）活性的调节剂（例如用于治疗哮喘）。